-
Jiang Ningjun joins Hengrui Pharmaceutical! Together with Sun Piaoyang and Zhang Lianshan, he formed a strategic R&D trio
Time of Update: 2023-02-03
From retirement to leaving the mountain, as of January 3, 2023, Sun Piaoyang has been in charge of Hengrui for more than 540 days. At present, Hengrui Pharmaceutical is still not performing well in th
-
Buy wire is preferred, this brand is a bit cattle
Time of Update: 2022-11-28
Recently, the results of the comprehensive strength evaluation of China's real estate development enterprises in 2021 were officially released, and the much-watched "Top 500 Comprehensive Strength of
-
Associate Professor Ma Hao, Shaanxi Normal University, et al.: Research progress on multi-scale structural characteristics of different types of resistant starch and the regulatory function
Time of Update: 2022-11-04
Jinxiu Zhang, Xinzhong Hu and Hao Ma from the College of Food Engineering and Nutritional Sciences, Shaanxi Normal University* introduced the apparent morphological structure and multi-scale structure characteristics of different types of resistant starch, compared the effects of different types of resistant starch on intestinal flora, SCFAs production, intestinal health and glycolipid metabolism, and analyzed and discussed the potential association between resistant starch types and intestinal microbiota regulatory function.
-
The launch of new domestic drugs is continuing to accelerate, and these types of drugs have become a hot track
Time of Update: 2022-08-19
Industry analysts believe that on the whole, the launch of new domestic drugs will continue to accelerate, and the three major tracks will be favored by pharmaceutical companies, with an increasingly broad market development space .
-
Locally advanced head and neck cancer is also curable
Time of Update: 2022-08-19
The results showed that after surgery-based comprehensive treatment, the 1-year survival rate of head and neck cancer patients was 88.
The results showed that after surgery-based comprehensive treatment, the 1-year survival rate of head and neck cancer patients was 88.
-
Alarm bells ring again
Time of Update: 2022-08-15
According to relevant laws and regulations, the Henan Provincial Food and Drug Administration issued a warning to the company and fined 160,000 yuan .
According to relevant laws and regulations, the Henan Provincial Food and Drug Administration issued a warning to the company and fined 160,000 yuan .
-
In 2022, a large number of domestic innovative drugs will gradually usher in the harvest period
Time of Update: 2022-04-30
Up to now, the number of innovative drugs approved for marketing by Hengrui Medicine has increased to 10 .
With the advancement of the research and development of innovative drugs in China, Fosun Pharma's innovative products have gradually entered the harvest period.
-
CSPC's anti-tumor drug revenue in 2021 exceeds 7 billion and more than 50 innovative drugs are ready to be launched
Time of Update: 2022-04-29
Innovative drugs continue to develop, and more than 30 models are expected to be launched in the next five years In 2021, CSPC's R&D investment has grown significantly again, exceeding 3 billion yuan for the first time, an increase of 18.
Heatmap of new drug targets under development by CSPC From: Insight Database Enterprise Analysis Module (http://db.
-
Significantly improve symptoms in Parkinson's disease patients with new mechanism therapy Phase 2 clinical results are positive
Time of Update: 2022-04-20
▲NETSseq technology platform (Image source: Cerevance's official website)In this randomized, double-blind, placebo-controlled Phase 2 clinical trial, approximately 135 Parkinson's disease patients received two different doses of CVN424 .
References:[1] Cerevance Reports Positive Phase 2 Clinical Trial Results with CVN424, a Parkinson's Disease Drug Working Through a New Mechanism.
-
The 3rd QbD Biopharmaceutical Quality Science Conference
Time of Update: 2022-04-15
In this context, how local pharmaceutical companies can go overseas on the premise of adhering to drug quality standards is the focus of this conference .
-
This drug market has huge potential, and the 180 billion blue ocean is about to set sail
Time of Update: 2022-03-05
With the active R&D and efforts of domestic and foreign pharmaceutical companies, a number of lung cancer drugs have been launched in China, bringing more choices for the treatment of lung cancer patients .
-
PARP inhibitor re-starts phase 0 clinical trials
Time of Update: 2021-12-05
AbbVie's PARP inhibitor Veliparib became the first drug to take a crab, and completed the first phase 0 clinical trial of a tumor drug.
-
Announcement of the State Drug Administration on 15 batches of drugs that do not meet the requirements (No. 49 of 2021
Time of Update: 2021-11-14
were inspected by the Gansu Institute for Drug Control and were not in compliance with the regulations, and the non-compliant items were impurity; labeled as Hebei The 5 batches of Bupleurum (North Bupleurum) produced by Yuekang Zhide Pharmaceutical Co.
-
The catalog of medical devices exempt from clinical evaluation, and the catalog of in vitro diagnostic reagents exempt from clinical trials are released
Time of Update: 2021-10-11
On September 18, in order to do a good job in the registration and management of medical devices, in accordance with the relevant registration and filing management measures, the State Food and Drug Administration organized and formulated the catalog of medical devices exempt from clinical evaluation and the catalog of in vitro diagnostic reagents exempt from clinical trials.
-
Analysis: the interaction between raw materials and auxiliary materials
Time of Update: 2021-06-30
The physical or chemical interaction between the drug and excipients will affect the bioavailability and stability of the drug; (2) It can help us understand the possible reactions before determining the final dosage form; (3) The compatibility of raw and auxiliary materials is essential for IND declaration .
